Bristol-Myers Squibb Company (BMY) Receives Consensus Rating of “Hold” from Brokerages

Bristol-Myers Squibb Company (NYSE:BMY) has earned a consensus rating of “Hold” from the twenty-two research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation and eleven have given a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $64.73.

BMY has been the subject of a number of recent research reports. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. Vetr cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $63.81 target price for the company. in a report on Wednesday, August 9th. Jefferies Group LLC reiterated a “buy” rating and issued a $66.00 target price (up previously from $63.00) on shares of Bristol-Myers Squibb in a report on Thursday, August 24th. UBS AG reiterated a “buy” rating and issued a $72.00 target price (up previously from $62.00) on shares of Bristol-Myers Squibb in a report on Friday, October 6th. Finally, Citigroup Inc. lifted their target price on Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a report on Wednesday, October 18th.

Bristol-Myers Squibb (BMY) traded down $0.55 during midday trading on Friday, reaching $61.32. The company’s stock had a trading volume of 3,932,622 shares, compared to its average volume of 5,594,304. The stock has a market cap of $100,362.45, a PE ratio of 20.72, a PEG ratio of 2.42 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. Bristol-Myers Squibb has a fifty-two week low of $46.01 and a fifty-two week high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by ($0.02). The firm had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.77 EPS. equities analysts predict that Bristol-Myers Squibb will post 2.99 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, November 1st. Investors of record on Friday, October 6th were given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 2.54%. The ex-dividend date was Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is currently 61.42%.

In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the sale, the senior vice president now owns 46,297 shares in the company, valued at approximately $2,777,820. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.23% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. Tradewinds Capital Management LLC boosted its stake in shares of Bristol-Myers Squibb by 34.6% in the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 500 shares during the last quarter. Atlantic Trust LLC purchased a new stake in shares of Bristol-Myers Squibb in the second quarter worth about $111,000. Massey Quick Simon & CO. LLC boosted its stake in shares of Bristol-Myers Squibb by 523.5% in the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 1,492 shares during the last quarter. Blue Chip Partners Inc. boosted its stake in shares of Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 17 shares during the last quarter. Finally, Proficio Capital Partners LLC boosted its stake in shares of Bristol-Myers Squibb by 29.6% in the first quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 504 shares during the last quarter. Hedge funds and other institutional investors own 68.97% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Bristol-Myers Squibb Company (BMY) Receives Consensus Rating of “Hold” from Brokerages” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/05/bristol-myers-squibb-company-bmy-receives-consensus-rating-of-hold-from-brokerages.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Analyst Recommendations for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply